PDF factsheet
      Z

anti inflammatory drugs in post myocardial infarction for all type of patients, clinical trials results

canakinumab versus placebo
CANTOS, 2017
NCT01327846
Quarterly Subcutaneous Canakinumab 50mg, 150mg, 300mg for 36 months
versus
placebo
Stable Post-myocardial Infarction Patients With Elevated hsCRPdouble-blind
Follow-up duration: 36 months

  Options


in first

in second

  Filter